This is a big threat to all the clients and BP customer base associated with Ronin Capital Managements new puppet masters....
Some big ties are just now coming in tying some old puzzle pieces with the new.....including Stason ....
I hope Peregrine exposes the past sabotage attempts with some of those ties to RCM and make all realize that Ronin also has an agenda because with this new "PLATFORM.."
Will Peregrine issue a Letter of their own? I say YES
Ronin and crew are afraid Avid and Peregrine advance on their own....
Antibody Discovery Platform is another interesting development. Why was this not PR'd if they were working to get over $1.00? Simple answer is that they had no intention of getting there. Ninety days remain for the current BOD, King and Lytle.
Thanks for pointing that out CJ. I found it quite interesting myself as soon as I saw it. That gives us one more VERY valuable asset to be used/monetized.
Number 5 was one reason that I was invested in Avanir years ago. You might remember that Avanir's platform (Xenerex) is where we got Bavi from. I would be glad to post those PRs from Avanir and Peregrine concerning those contracts if anyone is interested.
Let us make sure that no one steals our PEARL's from us, including the incumbent BOD.
My guess is the 8-2017 “EnAbl” trademark has to do with the new Avid “Antibody Discovery Platform” SK talked about in the 7-14-17 CC, and was added to the 4-30-17 10-K iss. 7-14-17...
S.King 7-14-17: “Another part of our effort to attract new customers is to expand our service offerings. Our scientists have developed a state-of-the-art Antibody Discovery & Characterization Platform through which we can generate antibodies against virtually any target. These capabilities are meant to allow rapid screening for high affinity antibodies that are developable. These capabilities are a natural extension of the services we already offer through Avid and it represents an attractive way to bringing customers at a much earlier stage of development with the potential to move them quickly into process developments and cGMP manufacturing. . . The Antibody Discovery Platform discussed earlier [Avid] could also be instrumental on the R&D side of the business, allowing us to rapidly identify antibodies against already validated targets, as well as the potential to identify novel targets. As we think about diversifying our development pipeline to include lower risk, already validated targets, this new capability could help us to identify developable antibodies that could have short-term value, as the need for such antibodies is on the rise. And this approach fits very well into our core capabilities and experience in the development of monoclonal antibodies. You can expect to hear more about this new capability over the coming months on both sides of our business.” http://tinyurl.com/yb4wulvu
= = = = = = = = = ENABL - Trademark Details – filed 8-1-17 Party Name: Peregrine Pharmaceuticals, Inc. https://trademarks.justia.com/875/51/enabl-87551219.html Goods/Svcs: “R&D services performed for others in the fields of pharmaceutical, medicinal and drug products; namely, R&D services performed for others and research under contract in the fields of antibody libraries, phages, phage display, identifying candidate therapeutic antibodies and manufacture of therapeutic antibodies.”
= = = = = = = = = = = = = = = = = = = = = = PPHM’s 4-30-17 10-K pub. 7-14-17 pg.5: Antibody Discovery Technology “Recently, our scientists have developed an antibody discovery and characterization platform through which we can generate antibodies against virtually any target. These capabilities are state-of-the-art and meant for rapid screening for high affinity antibodies as drug candidates. These capabilities are a natural extension of the services we already offer through Avid and it may represent a way to bring in customers at a much earlier stage of development with the potential to move them quickly into process development and cGMP manufacturing. Continuing to diversify our customer base is one of our key initiatives at Avid and we believe the antibody discovery capabilities will help attract new customers. The antibody discovery capabilities can also be used in our R&D business to rapidly identify antibodies against known targets as well as to identify novel targets. The antibody discovery platform is now fully functional and we are in the process of evaluating the technology through identifying several known targets and thus far, the results have looked promising. Once this process is completed, the technology platform will be marketed to potential customers as part of our CDMO service offerings.” http://tinyurl.com/ycxu4l5n
News 
Market Data 
Discover 
